Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | GBA1 | P04062 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14477978 | 1.00 | POLB (0.56) | POLBSMN1; SMN2L3MBTL1MEN1CYP2C19 | |
| SCHEMBL119623 | 1.00 | POLB (0.56) | POLBSMN1; SMN2L3MBTL1MEN1CYP2C19 | |
| SCHEMBL1283867 | 1.00 | POLB (0.56) | POLBSMN1; SMN2L3MBTL1MEN1CYP2C19 | |
| SCHEMBL8076306 | 1.00 | POLB (0.56) | POLBSMN1; SMN2L3MBTL1MEN1CYP2C19 | |
| SCHEMBL14477954 | 1.00 | POLB (0.56) | POLBSMN1; SMN2L3MBTL1MEN1CYP2C19 | |
| SCHEMBL15082405 | 1.00 | POLB (0.56) | POLBSMN1; SMN2L3MBTL1MEN1CYP2C19 | |
| SCHEMBL8084202 | 1.00 | POLB (0.56) | POLBSMN1; SMN2L3MBTL1MEN1CYP2C19 | |
| SCHEMBL2890516 | 1.00 | POLB (0.56) | POLBSMN1; SMN2L3MBTL1MEN1CYP2C19 | |
| SCHEMBL8084223 | 1.00 | POLB (0.56) | POLBSMN1; SMN2L3MBTL1MEN1CYP2C19 | |
| SCHEMBL14477956 | 1.00 | POLB (0.56) | POLBSMN1; SMN2L3MBTL1MEN1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 344 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3193849-A1 | OPIPRAMOL PATCH | Neuroderm, Ltd. (IL) | 2017-07-26 | — | — | EP | claimed |
| WO-2016042413-A1 | OPIPRAMOL PATCH | NEURODERM, LTD. (IL) | 2016-03-24 | — | — | WO | claimed |
| US-20120202891-A1 | Cannabinoid-Containing Compositions and Methods for Their Use | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2012-08-09 | — | — | US | claimed |
| EP-2424568-A1 | CANNABINOID-CONTAINING COMPOSITIONS AND METHODS FOR THEIR USE | University Of Kentucky Research Foundation (US) | 2012-03-07 | — | — | EP | claimed |
| US-7879344-B2 | contains antiitch agent; for use in wipes and absorbent articles, and transdermal patches | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2011-02-01 | — | — | US | claimed |
| WO-2010126501-A1 | CANNABINOID-CONTAINING COMPOSITIONS AND METHODS FOR THEIR USE | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-11-04 | — | — | WO | claimed |
| EP-2040693-A2 | TRANSDERMAL DELIVERY OF OLEOCANTHAL FOR RELIEF OF INFLAMMATION | Kimberly-Clark Worldwide, Inc. (US) | 2009-04-01 | — | — | EP | claimed |
| WO-2008001240-A2 | TRANSDERMAL DELIVERY OF OLEOCANTHAL FOR RELIEF OF INFLAMMATION | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2008-01-03 | — | — | WO | claimed |
| US-20080003273-A1 | Transdermal Delivery of Oleocanthal for Relief of Inflammation | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2008-01-03 | — | — | US | claimed |
| US-7137975-B2 | Method for increasing the battery life of an alternating current iontophoresis device using a barrier-modifying agent | ACIONT, INC. (US) | 2006-11-21 | — | — | US | claimed |
| US-20020161323-A1 | Method for increasing the battery life of an alternating current iontophoresis device using a barrier-modifying agent | ACIONT INC. | 2002-10-31 | — | — | US | claimed |
| EP-0813879-B1 | Drug administration composition for iontophoresis | HISAMITSU PHARMACEUTICAL CO (JP) | 2002-10-30 | — | — | EP | claimed |
| JP-2000512663-A | — | — | 2000-09-26 | — | — | JP | claimed |
| EP-1003469-A2 | FRAGRANCE PRECURSORS | GIVAUDAN-ROURE (INTERNATIONAL) S.A. (CH) | 2000-05-31 | — | — | EP | claimed |
| WO-1997030687-A2 | FRAGRANCE PRECURSORS | GIVAUDAN-ROURE (INTERNATIONAL) S.A. (CH) | 1997-08-28 | — | — | WO | claimed |
| US-12636309-B2 | Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions | ADORA ANIMAL HEALTH CORPORATION (US) | 2026-05-26 | — | — | US | disclosed |
| US-12636308-B2 | Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions | ADORA ANIMAL HEALTH CORPORATION (US) | 2026-05-26 | — | — | US | disclosed |
| CN-1171269-A | Drug administration composition for iontophoresis | HISAMITSU PHARMACEUTICAL CO (JP) | 1998-01-28 | — | — | CN | disclosed |
| EP-0813887-A2 | A device structure for iontophoresis | HISAMITSU PHARMACEUTICAL CO. INC. (JP) | 1997-12-29 | — | — | EP | disclosed |
| EP-0813879-A2 | Drug administration composition for iontophoresis | HISAMITSU PHARMACEUTICAL CO. INC. (JP) | 1997-12-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080003273-A1 | Transdermal Delivery of Oleocanthal for Relief of Inflammation | OXER1, OSBP, OXGR1 | POLB 2495/4885SMN1; SMN2 4130/4885L3MBTL1 4617/4885 |
| US-12636308-B2 | Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions | FUT6, CD44, CSGALNACT1 | POLB 3151/4885SMN1; SMN2 1287/4885L3MBTL1 4408/4885 |
| US-12636309-B2 | Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions | CD44, FUT8, FUT6 | POLB 3840/4885SMN1; SMN2 239/4885L3MBTL1 3320/4885 |
| US-20120202891-A1 | Cannabinoid-Containing Compositions and Methods for Their Use | CNR2, CNR1, FAAH | POLB 2397/4885SMN1; SMN2 2533/4885L3MBTL1 4725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.